A Cerebrovascular Event After Single-Dose Administration of Recombinant Factor VIIa in a Patient with Esophageal Variceal Bleeding

Akyıldız, Murat; Turan, Ilker; Özütemiz, Ömer; Batur, Yücel; İlter, Tankut

doi:10.1007/s10620-005-9023-y

Cited by 9 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The safety aspects of these trials have been reviewed recently [63]. Nevertheless, a few thrombotic events (i.e., cerebrovascular events, myocardial ischemia and portal vein thrombosis) in patients with advanced liver disease following rFVIIa administration have been reported [91,92], thus raising some concerns regarding its safety in this setting.…”

Section: Safety Issuesmentioning

confidence: 99%

The use of recombinant factor VIIa in liver diseases

Franchini

Montagnana²,

Targher³

et al. 2008

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Recombinant activated factor VII, a bypassing hemostatic agent originally developed for the treatment of hemorrhages in hemophilic patients with inhibitors, is increasingly being employed on a compassionate use basis for the treatment of uncontrolled massive bleeding from various causes. In this review, we present the current knowledge on the use of this agent in patients with severe coagulopathy due to end-stage liver disease. In particular, the role of recombinant activated factor VII for treating gastrointestinal bleeding episodes in patients with decompensated cirrhosis or for prophylaxis before liver surgical or invasive procedures will be addressed. The pathogenesis of complex coagulopathy in chronic liver diseases and the mechanisms by which recombinant activated factor VII might improve coagulation in such patients will also be described. Given the paucity of the published data and the lack of randomized trials, there is not enough evidence to support the extensive use of recombinant activated factor VII in any of the clinical indications analyzed. In conclusion, further large randomized, controlled clinical trials are needed to better define the role of recombinant activated factor VII in the treatment of bleeding complications of liver disorders.

show abstract

Section: Safety Issuesmentioning

confidence: 99%

The use of recombinant factor VIIa in liver diseases

Franchini

Montagnana²,

Targher³

et al. 2008

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…However, secondary myocardial and cerebrovascular infarctions have been described while using factor VIIa. 56,57 As such, it is important to stress once more that the use of this drug should always be carefully individualized.…”

Section: Recombinant Activated Factor Viiamentioning

confidence: 99%

Pharmacological Therapy for Recurrent Obscure Gastrointestinal Bleeding

Molina–Infante¹,

Vinagre-Rodríguez²,

Fernandez–Bermejo³

2011

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…Dado su marcado carácter protrombótico, se han descrito en la literatura accidentes vasculares a nivel cerebral o coronario asociados a su uso (51,52), especialmente en aquellos pacientes con factores de riesgo cardiovasculares, por lo que en este grupo de pacientes se debe ser cauto a la hora de sentar la indicación.…”

Section: Factor VII Recombinanteunclassified

Avances en el tratamiento farmacológico de la hemorragia digestiva de origen oscuro

Infante

Gallardo

Bermejo

2007

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

The development of capsule endoscopy and double-balloon enteroscopy has increased diagnostic and therapeutic rates in obscure gastrointestinal hemorrhage, where angiodysplasia of the small bowel is the most frequent cause. Nevertheless, almost 25-40% of patients who are not candidates or do not respond to endoscopic, angiographic, or surgical management may be at high risk of rebleeding, and therefore lack a clearly effective medical therapy. The utility of hormonal therapy remains unclear and is burdened by adverse effects. Subcutaneous octreotide usually controls bleeding but does not seem adequate for maintenance therapy. Non-selective beta-blockers alone or in combination with other treatments, as in the prophylaxis of portal hypertension variceal bleeding, may be helpful. Recently, octreotide LAR, a depot formulation administered once a month intramuscularly, and oral thalidomide, a powerful inhibitor of angiogenesis, have demonstrated their effectiveness and safety for long-term therapy in anecdotal case reports and deserve further investigation.

show abstract

A Cerebrovascular Event After Single-Dose Administration of Recombinant Factor VIIa in a Patient with Esophageal Variceal Bleeding

Cited by 9 publications

References 19 publications

The use of recombinant factor VIIa in liver diseases

The use of recombinant factor VIIa in liver diseases

Pharmacological Therapy for Recurrent Obscure Gastrointestinal Bleeding

Avances en el tratamiento farmacológico de la hemorragia digestiva de origen oscuro

Contact Info

Product

Resources

About